During the past decade, Providence Cancer Center conducted 35 clinical trials. In the 10-year time frame, 35 clinical trials started and 7 clinical trials were completed, i.e. on average, 20% percent of trials that started reached the finish line to date. In the past 5 years, 20 clinical trials started and 4 clinical trials were completed. i.e. 20% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Providence Cancer Center" #1 sponsor was "Providence Health & Services" with 7 trials, followed by "Aeglea Biotherapeutics" with 2 trials sponsored, "Celgene" with 2 trials sponsored, "Hoffmann-La Roche" with 2 trials sponsored and "Seagen Inc." with 2 trials sponsored. Other sponsors include 30 different institutions and companies that sponsored additional 40 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Providence Cancer Center" #1 collaborator was "Merck Sharp & Dohme LLC" with 5 trials as a collaborator, "Prometheus Laboratories" with 2 trials as a collaborator, "Providence Cancer Center, Earle A. Chiles Research Institute" with 2 trials as a collaborator, "Aduro Biotech, Inc." with 1 trials as a collaborator and "Agenus Inc." with 1 trials as a collaborator. Other collaborators include 8 different institutions and companies that were collaborators in the rest 18 trials.

According to Clinical.Site data, the most researched conditions in "Providence Cancer Center" are "Melanoma" (7 trials), "Breast Cancer" (6 trials), "Head and Neck Cancer" (4 trials), "Advanced Cancer" (3 trials) and "Gastric Cancer" (3 trials). Many other conditions were trialed in "Providence Cancer Center" in a lesser frequency.

Most popular intervention types in "Providence Cancer Center" are "Drug" (40 trials), "Biological" (15 trials), "Dietary Supplement" (3 trials), "Procedure" (2 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Pembrolizumab" (7 trials), "Paclitaxel" (4 trials), "Capecitabine" (3 trials), "Carboplatin" (3 trials) and "Nivolumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Providence Cancer Center" are 45 trials for "All" genders, 4 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Providence Cancer Center". undefined are not yet recruiting, 16 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 19 completed trials in Providence Cancer Center, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Providence Cancer Center, 27 "Phase 1" clinical trials were conducted, 29 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".